H.C. Wainwright raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $100 from $95 and keeps a Buy rating on the shares. The firm recommends buying the shares of the American Heart Association meeting next month. The firm sees a potential $4B sales opportunity for olezarsen. Talks with management suggest “deeper efficacy, wider reach, and defensible mid-teens pricing,” the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $94 from $90 at Morgan Stanley
- Ionis Pharmaceuticals price target raised to $99 from $59 at TD Cowen
- Ionis Pharmaceuticals: Strong Q3 Performance and Promising Future Catalysts Support Buy Rating
- Ionis Pharmaceuticals price target raised to $95 from $80 at Barclays
- Ionis Pharmaceuticals: Strong Q3 Performance and Promising Pipeline Drive Buy Rating